The vyjuvek market research report is one of a series of new reports that provides vyjuvek market statistics, including the vyjuvek industry's global market size, regional shares, competitors with a vyjuvek market share, detailed vyjuvek market segments, market trends and opportunities, and any further data you may need to thrive in the vyjuvek industry. This vyjuvek market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to rising healthcare expenditure, growing focus on personalized medicine, increasing patient access to gene therapy, expanded regulatory support for innovative therapies, and growing healthcare infrastructure in emerging markets. Major trends in the forecast period include accelerated adoption of gene therapies, integration of digital health technologies for treatment monitoring, emergence of regional manufacturing hubs, rise in public-private collaborations, and development of more scalable production methods.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the Vyjuvek market in the future. Chronic diseases are long-term health conditions that typically persist for a year or more, requiring continuous medical management and often limiting everyday activities. Factors such as aging populations, poor lifestyle choices, urbanization, and increased exposure to environmental risk factors are contributing to the rise in chronic conditions. Vyjuvek is designed to treat chronic diseases such as dystrophic epidermolysis bullosa (DEB) by delivering a functional COL7A1 gene via its topical gel formulation. This treatment helps produce type VII collagen, which strengthens the skin’s structure, promotes wound healing, reduces the frequency and severity of chronic wounds, and improves the quality of life for patients with this debilitating condition. For example, Allergy UK reported in April 2024 that over 21 million people in the UK were affected by allergies in 2022, making allergies the most common chronic health condition in the country. Projections suggest that by 2026, half of Europe’s population will experience at least one allergy. As chronic diseases become more prevalent, the Vyjuvek market is expected to grow.
The growing demand for personalized medicine is also expected to drive the Vyjuvek market in the coming years. Personalized medicine tailors treatments based on an individual's genetic, environmental, and lifestyle factors, and is gaining momentum due to advancements in genomics, technology, and data analysis. These innovations enable more precise, effective, and customized treatment options. Vyjuvek aligns with personalized medicine by providing a topical gene therapy specifically designed to address the genetic cause of dystrophic epidermolysis bullosa (DEB). This allows for targeted treatment that suits individual patient needs, genetic profiles, and clinical conditions, improving outcomes. According to a 2023 report by the Personalized Medicine Coalition, personalized medicines accounted for 35% of newly approved NMEs in 2021, and with 12 new approvals in 2022, they have consistently represented at least a quarter of new drug approvals over the past eight years, a significant increase from under 10% a decade ago. This growing focus on personalized medicine is a key driver of the Vyjuvek market.
An important trend in the Vyjuvek market is the development of innovative treatments, such as the first-ever redosable gene therapy for dystrophic epidermolysis bullosa (DEB). This approach enables multiple administrations of gene therapy, helping to maintain or enhance therapeutic effects over time and address progressive conditions more effectively. In May 2023, Krystal Biotech Inc. announced that Vyjuvek (beremagene geperpavec-svdt), the first-ever redosable gene therapy, received FDA approval for treating DEB. This topical gel directly targets the genetic cause of DEB by restoring functional copies of the COL7A1 gene, allowing for improved wound healing and sustained production of collagen. Its approval marks a significant milestone, as it is the first FDA-approved treatment for DEB that is safe, non-invasive, and can be administered both in clinical settings and at home. This groundbreaking development represents a transformative step forward in treating genetic disorders such as DEB.
The key company operating in the vyjuvek market is Krystal Biotech Inc.
North America was the largest region in the vyjuvek market in 2024. The regions covered in vyjuvek report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vyjuvek market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vyjuvek is a topical gene therapy developed to treat dystrophic epidermolysis bullosa (DEB) by delivering functional COL7A1 genes to affected skin cells, promoting sustained collagen production and wound healing. It helps restore skin integrity and accelerate healing in individuals with DEB by targeting the genetic root cause of the condition. Vyjuvek is the first redosable gene therapy approved for this rare genetic disorder.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Vyjuvek include epidermolysis bullosa (EB) and dystrophic epidermolysis bullosa (DEB). Epidermolysis bullosa (EB) refers to a group of rare genetic conditions that cause the skin to be extremely fragile, resulting in blisters from even minor trauma. These conditions stem from mutations in proteins that normally bind the skin layers together, causing the skin to separate. Vyjuvek is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a wide range of patients, including adults, children, and elderly individuals.
The vyjuvek market consists of sales of topical gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising healthcare expenditure, growing focus on personalized medicine, increasing patient access to gene therapy, expanded regulatory support for innovative therapies, and growing healthcare infrastructure in emerging markets. Major trends in the forecast period include accelerated adoption of gene therapies, integration of digital health technologies for treatment monitoring, emergence of regional manufacturing hubs, rise in public-private collaborations, and development of more scalable production methods.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the Vyjuvek market in the future. Chronic diseases are long-term health conditions that typically persist for a year or more, requiring continuous medical management and often limiting everyday activities. Factors such as aging populations, poor lifestyle choices, urbanization, and increased exposure to environmental risk factors are contributing to the rise in chronic conditions. Vyjuvek is designed to treat chronic diseases such as dystrophic epidermolysis bullosa (DEB) by delivering a functional COL7A1 gene via its topical gel formulation. This treatment helps produce type VII collagen, which strengthens the skin’s structure, promotes wound healing, reduces the frequency and severity of chronic wounds, and improves the quality of life for patients with this debilitating condition. For example, Allergy UK reported in April 2024 that over 21 million people in the UK were affected by allergies in 2022, making allergies the most common chronic health condition in the country. Projections suggest that by 2026, half of Europe’s population will experience at least one allergy. As chronic diseases become more prevalent, the Vyjuvek market is expected to grow.
The growing demand for personalized medicine is also expected to drive the Vyjuvek market in the coming years. Personalized medicine tailors treatments based on an individual's genetic, environmental, and lifestyle factors, and is gaining momentum due to advancements in genomics, technology, and data analysis. These innovations enable more precise, effective, and customized treatment options. Vyjuvek aligns with personalized medicine by providing a topical gene therapy specifically designed to address the genetic cause of dystrophic epidermolysis bullosa (DEB). This allows for targeted treatment that suits individual patient needs, genetic profiles, and clinical conditions, improving outcomes. According to a 2023 report by the Personalized Medicine Coalition, personalized medicines accounted for 35% of newly approved NMEs in 2021, and with 12 new approvals in 2022, they have consistently represented at least a quarter of new drug approvals over the past eight years, a significant increase from under 10% a decade ago. This growing focus on personalized medicine is a key driver of the Vyjuvek market.
An important trend in the Vyjuvek market is the development of innovative treatments, such as the first-ever redosable gene therapy for dystrophic epidermolysis bullosa (DEB). This approach enables multiple administrations of gene therapy, helping to maintain or enhance therapeutic effects over time and address progressive conditions more effectively. In May 2023, Krystal Biotech Inc. announced that Vyjuvek (beremagene geperpavec-svdt), the first-ever redosable gene therapy, received FDA approval for treating DEB. This topical gel directly targets the genetic cause of DEB by restoring functional copies of the COL7A1 gene, allowing for improved wound healing and sustained production of collagen. Its approval marks a significant milestone, as it is the first FDA-approved treatment for DEB that is safe, non-invasive, and can be administered both in clinical settings and at home. This groundbreaking development represents a transformative step forward in treating genetic disorders such as DEB.
The key company operating in the vyjuvek market is Krystal Biotech Inc.
North America was the largest region in the vyjuvek market in 2024. The regions covered in vyjuvek report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vyjuvek market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vyjuvek is a topical gene therapy developed to treat dystrophic epidermolysis bullosa (DEB) by delivering functional COL7A1 genes to affected skin cells, promoting sustained collagen production and wound healing. It helps restore skin integrity and accelerate healing in individuals with DEB by targeting the genetic root cause of the condition. Vyjuvek is the first redosable gene therapy approved for this rare genetic disorder.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Vyjuvek include epidermolysis bullosa (EB) and dystrophic epidermolysis bullosa (DEB). Epidermolysis bullosa (EB) refers to a group of rare genetic conditions that cause the skin to be extremely fragile, resulting in blisters from even minor trauma. These conditions stem from mutations in proteins that normally bind the skin layers together, causing the skin to separate. Vyjuvek is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a wide range of patients, including adults, children, and elderly individuals.
The vyjuvek market consists of sales of topical gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. VYJUVEK Market Characteristics4. VYJUVEK Market Trends And Strategies5. VYJUVEK Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global VYJUVEK Pricing Analysis & Forecasts30. Global VYJUVEK Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The VYJUVEK Market32. Recent Developments In The VYJUVEK Market
3. VYJUVEK Market Biologic Drug Characteristics
6. Global VYJUVEK Growth Analysis And Strategic Analysis Framework
8. VYJUVEK Market Segmentation
9. Global VYJUVEK Epidemiology Of Clinical Indications
10. VYJUVEK Market Regional And Country Analysis
11. Asia-Pacific VYJUVEK Market
12. China VYJUVEK Market
13. India VYJUVEK Market
14. Japan VYJUVEK Market
15. Australia VYJUVEK Market
16. South Korea VYJUVEK Market
17. Western Europe VYJUVEK Market
18. UK VYJUVEK Market
19. Germany VYJUVEK Market
20. France VYJUVEK Market
21. Eastern Europe VYJUVEK Market
22. North America VYJUVEK Market
23. USA VYJUVEK Market
24. Canada VYJUVEK Market
25. South America VYJUVEK Market
26. Middle East VYJUVEK Market
27. Africa VYJUVEK Market
28. VYJUVEK Market Competitive Landscape And Company Profiles
29. Global VYJUVEK Market Pipeline Analysis
33. VYJUVEK Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
VYJUVEK Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vyjuvek market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vyjuvek ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vyjuvek market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Epidermolysis Bullosa (EB); Dystrophic Epidermolysis Bullosa (DEB)2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Pediatric; Geriatric
Key Companies Profiled: Krystal Biotech Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Krystal Biotech Inc.
